Narrow search
Showing 1 - 10 of 9,696
Cover Image
The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: evidence from an online experiment
Wettstein, Dominik J.; Boes, Stefan - In: Health economics review 10 (2020) 13, pp. 1-15
Background: The necessity to measure and reward "value for money" of new pharmaceuticals has become central in health … study assesses the impact of a negotiation situation for lifeextending pharmaceuticals on societal outcomes. Of interest … into four treatment groups for a reimbursement negotiation between two roles (health minister, pharma representative) in …
Persistent link: https://www.econbiz.de/10012291180
Cover Image
Reimbursement and clinical guidance for pharmaceuticals in Sweden
Anell, Anders; Persson, Ulf - In: The European Journal of Health Economics 6 (2005) 3, pp. 274-279
Persistent link: https://www.econbiz.de/10009404270
Cover Image
The impact of reimbursement negotiations on cost and availability of new pharmaceuticals: Evidence from an online experiment
Wettstein, Dominik J.; Boes, Stefan - In: Health Economics Review 10 (2020) 13, pp. 1-15
Background: The necessity to measure and reward "value for money" of new pharmaceuticals has become central in health … study assesses the impact of a negotiation situation for lifeextending pharmaceuticals on societal outcomes. Of interest … into four treatment groups for a reimbursement negotiation between two roles (health minister, pharma representative) in …
Persistent link: https://www.econbiz.de/10014489832
Cover Image
Value-based differential pricing : efficient prices for drugs in a global context
Danzon, Patricia Munch; Towse, Adrian; Mestre … - In: Health economics 24 (2015) 3, pp. 294-301
Persistent link: https://www.econbiz.de/10011317796
Cover Image
Valuing trial designs from a pharmaceutical perspective using value-based pricing
Breeze, Penny; Brennan, Alan - In: Health economics 24 (2015) 11, pp. 1468-1482
Persistent link: https://www.econbiz.de/10011433995
Cover Image
Value based pricing of pharmaceuticals in the US and UK : does centralized cost effectiveness analysis matter?
Comanor, William S.; Schweitzer, Stuart O.; Riddle, Jon M. - In: Review of industrial organization : RIO 52 (2018) 4, pp. 589-602
Persistent link: https://www.econbiz.de/10012008043
Cover Image
Does drug price-regulation affect healthcare expenditures?
Ben-Aharon, Omer; Shavit, Oren; Magnezi, Racheli - In: The European journal of health economics : HEPAC ; … 18 (2017) 7, pp. 859-867
Persistent link: https://www.econbiz.de/10011869108
Cover Image
Multiple criteria decision analysis for value based assessment of new medical technologies: a conceptual framework
Kanavos, Panos; Angelis, Aris - London School of Economics (LSE) - 2013
Assessing the value of new medical technologies may require new approaches that take into account a more comprehensive set of parameters than the incremental cost/QALY. It is argued that MCDA can fulfil this role and has the potential to be methodologically superior to the currently used...
Persistent link: https://www.econbiz.de/10010884583
Cover Image
Rethinking value in health innovation : from mystifications towards prescriptions
Mazzucato, Mariana; Roy, Victor - In: Journal of economic policy reform 22 (2019) 2, pp. 101-119
Persistent link: https://www.econbiz.de/10012177039
Cover Image
Dynamic Cost-Effectiveness: A More Efficient Reimbursement Criterion
Lundin, Douglas; Ramsberg, Joakim - In: Forum for Health Economics & Policy 11 (2008) 2
Basing drug reimbursement on cost-effectiveness provides too little incentives for R&D. The reason for this is that … protection is too high to warrant reimbursement according to the cost-effectiveness decision rule. We show in a theoretical model …
Persistent link: https://www.econbiz.de/10014591975